Home › All Companies › BCAX › Quarterly Report

Bicara Therapeutics Inc. (BCAX) — Quarterly Report

AI-Powered SEC Filing Analysis

← All BCAX filings
Latest Quarterly Report Filed: 2026-05-11

Key Insights

  • Bicara completed a February 2026 secondary offering including common stock and pre-funded warrants, indicating capital raising activity to fund operations and R&D initiatives.
  • The company maintains an active ATM (at-the-market) program established in December 2025, providing flexible access to capital markets for future funding needs.
  • Recent stock option and inducement plan activities (2024 Stock Option Plan and January 2026 Inducement Plan) suggest ongoing employee equity compensation and potential talent acquisition efforts.
  • Multiple related party agreements with entities like Syngene, BBL, and IQVIA indicate substantial outsourced R&D and clinical services dependencies that could impact operational efficiency and costs.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Bicara Therapeutics Inc.

Current Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.